Đăng nhập
 
Tìm kiếm nâng cao
 
Tên bài báo
Tác giả
Năm xuất bản
Tóm tắt
Lĩnh vực
Phân loại
Số tạp chí
 

Bản tin định kỳ
Báo cáo thường niên
Tạp chí khoa học ĐHCT
Tạp chí tiếng anh ĐHCT
Tạp chí trong nước
Tạp chí quốc tế
Kỷ yếu HN trong nước
Kỷ yếu HN quốc tế
Book chapter
Bài báo - Tạp chí
5 (2015) Trang: 22066-22074
Tạp chí: RSC Advances

Zerumbone is a potential anti-inflammatory, immunomodulatory and anti-tumor agent. However, the major problems that prevent the in vivo and even clinical applications of Zerumbone are its water insolubility that compromises its bioavailability. To enhance the bioavailability and efficacy of Zerumbone, nanostructured lipid carriers (NLC) were used to encapsulate Zerumbone. NLC–Zerumbone has been reported to have a slow release, comparable in vitro cytotoxicity against leukemia and breast cancer, and no observed in vivo oral acute toxicity. However, the in vivoantitumor effect of NLC–Zerumbone is still unknown. The anti-tumor, immunostimulatory and anti-inflammatory effects of Zerumbone and NLC–Zerumbone in 4T1 challenged mice were compared in this study. Zerumbone effectively controlled the tumor growth and metastasis viadelaying the cancer cell cycle progression and apoptosis. Besides, Zerumbone also enhanced the anti-tumor immunity and anti-inflammatory effects. NLC encapsulation was found to further improve the anti-tumor, immunomodulation, anti-inflammation and anti-metastatic efficacy of Zerumbone in 4T1 challenged mice. This study provides the possibility of utilizing NLC encapsulated Zerumbone for breast cancer therapy.



Graphical abstract: Nanostructured lipid carrier improved in vivo anti-tumor and immunomodulatory effect of Zerumbone in 4T1 challenged mice
Các bài báo khác
 

Crossref DOI of CTUJoS


BC thường niên 2018


Con số ấn tượng (VN | EN)


Bản tin ĐHCT


TCKH tiếng Việt


TCKH tiếng Anh

 
 
Vui lòng chờ...